Prothena Co. plc (NASDAQ:PRTA – Get Ranking) Director Richard T. Collier bought 5,000 shares of the inventory in a transaction on Monday, November seventh. The shares have been bought at a median value of $55.62, for a complete transaction of $278,100.00. Following the completion of the transaction, the director now owns 1,219 shares of the corporate’s inventory, valued at roughly $67,800.78. The sale was disclosed in a submitting with the SEC, which is accessible by way of this hyperlink.
Prothena Worth Efficiency
Shares of NASDAQ PRTA traded down $3.87 throughout mid-day buying and selling on Wednesday, hitting $52.05. The corporate’s inventory had a buying and selling quantity of 446,848 shares, in comparison with its common quantity of 519,784. The inventory has a market cap of $2.52 billion, a price-to-earnings ratio of -15.58 and a beta of 0.48. Prothena Co. plc has a one yr low of $21.06 and a one yr excessive of $65.35. The corporate’s fifty day easy transferring common is $46.83 and its 200-day easy transferring common is $35.04.
Prothena (NASDAQ:PRTA – Get Ranking) final issued its earnings outcomes on Monday, August eighth. The biotechnology firm reported ($0.88) earnings per share (EPS) for the quarter, lacking the consensus estimate of ($0.51) by ($0.37). The enterprise had income of $1.31 million throughout the quarter, in comparison with the consensus estimate of $20.12 million. Prothena had a unfavorable web margin of three,036.03% and a unfavorable return on fairness of 36.46%. On common, sell-side analysts predict that Prothena Co. plc will put up -2.51 EPS for the present yr.
Analyst Upgrades and Downgrades
Various equities analysts have not too long ago issued experiences on PRTA shares. JMP Securities elevated their value goal on shares of Prothena from $50.00 to $81.00 in a analysis be aware on Wednesday, September twenty eighth. StockNews.com started protection on shares of Prothena in a report on Wednesday, October twelfth. They issued a “maintain” score on the inventory. Financial institution of America raised shares of Prothena from a “impartial” score to a “purchase” score and elevated their value goal for the inventory from $45.00 to $65.00 in a report on Wednesday, September twenty eighth. Royal Financial institution of Canada lowered shares of Prothena from an “outperform” score to a “sector carry out” score and elevated their value goal for the inventory from $52.00 to $55.00 in a report on Friday, November 4th. They famous that the transfer was a valuation name. Lastly, Oppenheimer elevated their value goal on shares of Prothena from $100.00 to $110.00 and gave the inventory an “outperform” score in a report on Thursday, September twenty ninth. Two analysts have rated the inventory with a maintain score and 4 have issued a purchase score to the corporate’s inventory. In line with knowledge from MarketBeat.com, Prothena has a median score of “Reasonable Purchase” and a median goal value of $76.40.
Institutional Buying and selling of Prothena
Hedge funds have not too long ago modified their holdings of the corporate. China Common Asset Administration Co. Ltd. acquired a brand new stake in shares of Prothena within the third quarter valued at roughly $27,000. Lazard Asset Administration LLC raised its place in shares of Prothena by 61.1% within the 1st quarter. Lazard Asset Administration LLC now owns 1,733 shares of the biotechnology firm’s inventory valued at $63,000 after buying a further 657 shares throughout the interval. Point72 Hong Kong Ltd acquired a brand new stake in shares of Prothena within the 1st quarter valued at roughly $141,000. Hunter Perkins Capital Administration LLC acquired a brand new stake in shares of Prothena within the third quarter valued at roughly $249,000. Lastly, Virtus ETF Advisers LLC raised its place in shares of Prothena by 22.7% within the 2nd quarter. Virtus ETF Advisers LLC now owns 4,523 shares of the biotechnology firm’s inventory valued at $123,000 after buying a further 837 shares throughout the interval. 93.92% of the inventory is at present owned by institutional traders and hedge funds.
About Prothena
(Get Ranking)
Prothena Company plc, a late-stage medical firm, focuses on discovery and growth of novel therapies for life-threatening ailments in the US. The corporate is concerned in creating Birtamimab, an investigational humanized antibody that’s in Section III medical trial for the therapy of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Section IIb medical trial for the therapy of Parkinson’s illness; PRX004 that accomplished Section I medical trial for the therapy of Transthyretin amyloidosis; and PRX005, which is in Section I medical trial for the therapy of Alzheimer’s illness.
Learn Extra
This immediate information alert was generated by narrative science expertise and monetary knowledge from MarketBeat with a purpose to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you take into account Prothena, you will need to hear this.
MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their shoppers every day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Prothena wasn’t on the listing.
Whereas Prothena at present has a “Reasonable Purchase” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.
View The 5 Shares Right here
